Yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma
Matthew S McKinney, Anne W Beaven Division of Hematologic Malignancies, Department of Medicine, Duke University Medical Center, Durham, NC, USA Abstract: Most cases of indolent non-Hodgkin lymphoma (NHL) are incurable with standard chemoimmunotherapy approaches, and patients with relapsed/refracto...
Guardado en:
Autores principales: | McKinney MS, Beaven AW |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b9627e99554348259522087327de8adb |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
ANTICARDIOLIPINIC ANTIBODIES IN NON-HODGKIN LYMPHOMA
por: Sanda Buruiana, et al.
Publicado: (2021) -
MicroRNA dysregulation in B-cell non-Hodgkin lymphoma
por: Lim EL, et al.
Publicado: (2013) -
MEDICAL TREATMENT IN HODGKIN LYMPHOMA
por: Nilgun Kurucu
Publicado: (2021) -
PROGNOSIS FACTORS IN AGGRESSIVE NON-HODGKIN LYMPHOMAS WITH PRIMARY INVOLVEMENT OF THE SPLEEN
por: Larisa Musteata, et al.
Publicado: (2021) -
Intrasinusoidal Hodgkin Lymphoma; A Mimic of Anaplastic Large Cell Lymphoma
por: John R. Krause, et al.
Publicado: (2021)